Study #2024-0425
A phase 1, open-label, multicenter study of INCB161734 in participants with advanced or metastatic solid tumors with KRAS G12D mutation
MD Anderson Study Status
Enrolling
Treatment Agent
INCB161734, Cetuximab, Retifanlimab, GEMNabP, mFOLFIRINOX
Description
This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Solid Tumors
Study phase:
Phase I
Physician name:
Shubham Pant
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-790-1139
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.